Generics Bulletin is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


Amneal Has The Firepower To Pursue Injectables Deals

Executive Summary

With integration of the merger between Amneal and Impax largely completed, the US-focused group is on the look-out for deals to boost its generic injectables portfolio.

You may also be interested in...

If Amneal Goes Global Again, It Intends To Go Big

Having just sold off relatively small operations in the UK and Germany, Amneal would look for large-scale deals if it were to expand again beyond its US powerbase. The US generics and specialty brands company is also looking to expand its injectables business and is considering a move into biosimilar insulins.

Combined Amneal adds bevacizumab and Gemini

Amneal has struck a licensing deal with Mabxience for exclusive US rights to biosimilar Avastin (bevacizumab) and has acquired branded player and hybrid 505(b)(2) specialist Gemini Laboratories for US$117 million, at the same time as announcing the completion of its merger with Impax, creating the “fifth-largest US generics player”.

Pressure Mounts For German Tender Reforms

Germany’s off-patent industry association, Pro Generika, is finding ample support for its position that by awarding tender contracts to exclusive suppliers, health insurance funds are contributing to drug shortages in the country.


Latest News
See All



Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts